The Thesis
The premise is clean and intuitive: buy when recent news sentiment turns positive, exit when it turns negative. The strategy runs across a 24-name blue-chip universe spanning big tech (AAPL, MSFT, GOOGL, NVDA), financials (JPM, BAC, V, MA), healthcare (JNJ, UNH, PFE, ABBV), and staples/industrials (PG, KO, WMT, COST, CAT, XOM). It is currently flagged live.
Sentiment-driven entries are a well-worn idea, and on a liquid large-cap universe the mechanics are sound. The trouble, as the data shows, is not the thesis — it's how rarely the signal actually fires.
Recent Activity
The live account is effectively idle. Every scheduled run from August 10 through August 17 reports the same line: 0 executed, 0 rejected, cash pinned at $990.06, total equity drifting between roughly $10,287 and $10,506. No sentiment threshold has been crossed in over a week.
The last real activity was earlier in the summer — a cluster of buys in AAPL (May 31), MSFT (June 3), BAC (June 12), UNH (June 18), and GOOGL (July 1). Since then, nothing. This is a strategy holding a handful of positions and waiting, not one actively rotating on fresh sentiment.
Backtest & Validation
The headline backtest numbers are underwhelming and, frankly, negligible in scale:
- Total return: +0.19% over 451 days (CAGR ~0.10%)
- Sharpe: 0.74
- Max drawdown: 0.05%
- Trades: just 2, with a 0% win rate
- Turnover: 36.5%, total fees: $2
A 0% win rate paired with a small positive return means the arithmetic here rests on almost nothing — two trades is not a sample, it's an anecdote.
Walk-forward validation makes the fragility explicit. Across four folds, only one was positive — and it's the same fold carrying the entire result. Folds 1–3 (Aug 2024 through Dec 2025) each produced zero trades and zero return. Only fold 4 (Dec 2025–May 2026) traded at all, delivering the full +0.19% at a 1.5 Sharpe. The out-of-sample numbers simply echo that single window.
The risk-adjusted diagnostics are mixed: PSR of 0.923 looks reassuring, but the deflated Sharpe (DSR) of 0.551 — which penalizes for 6 trials — sits right at the coin-flip line. Unsurprisingly, validation returns passed: false.
The Verdict
Strengths: the drawdown is trivially small, fees are near zero, and the thesis is defensible. When it did trade in fold 4, the result was clean.
Risks: this is a strategy that essentially doesn't trade. Three of four folds are flat, all performance stems from one window, and the DSR flags that even that may not survive multiple-testing scrutiny. Running it live despite a failed validation gate is the real concern — there is no edge to speak of yet, only a signal too quiet to test. Until the sentiment trigger fires often enough to build a real sample, treat these numbers as noise, not signal.